Supplementary Figure S2 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
Abstract
Brentuximab and derivatives show high affinity binding to CD30 and strongly internalize into CD30-positive cells
Fields of Study & Subjects
Lymphoma Diagnosis and Treatment
Monoclonal and Polyclonal Antibodies Research
Protein Degradation and Inhibitors
Publication details
- Publication date
- 4 February 2026